JP7780434B2 - 抗ｃｄ１９抗体および多重特異性結合タンパク質 - Google Patents

抗ｃｄ１９抗体および多重特異性結合タンパク質

Info

Publication number
JP7780434B2
JP7780434B2 JP2022535811A JP2022535811A JP7780434B2 JP 7780434 B2 JP7780434 B2 JP 7780434B2 JP 2022535811 A JP2022535811 A JP 2022535811A JP 2022535811 A JP2022535811 A JP 2022535811A JP 7780434 B2 JP7780434 B2 JP 7780434B2
Authority
JP
Japan
Prior art keywords
antigen
binding site
seq
certain embodiments
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506017A (ja
JP2023506017A5 (https=
Inventor
パトリック エー． バウアリー
ジェニファー マイケルソン
ポチョン イ
ナヴィーン メータ
ジョナサン ベルク
ネイサン シャーキー
ビアンカ プリンツ
ブラッドリー エム． ルンデ
ガー レワ ヒューストン
Original Assignee
カリナン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリナン セラピューティクス インコーポレイテッド filed Critical カリナン セラピューティクス インコーポレイテッド
Publication of JP2023506017A publication Critical patent/JP2023506017A/ja
Publication of JP2023506017A5 publication Critical patent/JP2023506017A5/ja
Application granted granted Critical
Publication of JP7780434B2 publication Critical patent/JP7780434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022535811A 2019-12-11 2020-12-11 抗ｃｄ１９抗体および多重特異性結合タンパク質 Active JP7780434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946931P 2019-12-11 2019-12-11
US62/946,931 2019-12-11
PCT/US2020/064706 WO2021119551A1 (en) 2019-12-11 2020-12-11 Anti-cd19 antibodies and multi-specific binding proteins

Publications (3)

Publication Number Publication Date
JP2023506017A JP2023506017A (ja) 2023-02-14
JP2023506017A5 JP2023506017A5 (https=) 2023-12-15
JP7780434B2 true JP7780434B2 (ja) 2025-12-04

Family

ID=76329102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535811A Active JP7780434B2 (ja) 2019-12-11 2020-12-11 抗ｃｄ１９抗体および多重特異性結合タンパク質

Country Status (8)

Country Link
US (1) US12428480B2 (https=)
EP (1) EP4073122A4 (https=)
JP (1) JP7780434B2 (https=)
CN (1) CN115916818A (https=)
AU (1) AU2020403273A1 (https=)
CA (1) CA3161283A1 (https=)
IL (1) IL293725A (https=)
WO (1) WO2021119551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
KR20260020379A (ko) * 2023-04-07 2026-02-11 쿨리난 테라퓨틱스, 인코포레이티드 다중특이적 결합 단백질의 사용 방법
WO2025165980A1 (en) * 2024-01-31 2025-08-07 Cullinan Therapeutics, Inc. Therapies for autoimmune disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500725A (ja) 2007-10-19 2011-01-06 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US10000574B2 (en) 2003-11-28 2018-06-19 Amgen Research (Munich) Gmbh Compositions comprising polypeptides
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
HRP20150175T1 (en) 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013013700A1 (en) 2011-07-22 2013-01-31 Affimed Therapeutics Ag Multivalent antigen-binding fv molecule
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
JP2017512814A (ja) 2014-04-07 2017-05-25 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
CN107406507A (zh) 2015-02-12 2017-11-28 西雅图基因公司 使用cd19‑adc和长春新碱的组合疗法
CN114920848B (zh) 2015-05-13 2024-10-11 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017055314A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
AU2016330807B2 (en) * 2015-10-02 2023-08-10 F. Hoffmann-La Roche Ag Anti-human CD19 antibodies with high affinity
AU2016357460B2 (en) * 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CN105399832A (zh) 2015-12-07 2016-03-16 四川大学 一种无标签单链型人源双特异性抗体及其用途
KR20180133442A (ko) 2016-04-13 2018-12-14 비비아 바이오테크 에스.엘. 생체외 bite 활성화된 t 세포
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
FR3068662B1 (fr) 2017-07-04 2019-08-30 Le Joint Francais Snc Passe-cloison pour un organe destine a traverser une cloison
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP7383704B2 (ja) * 2018-06-07 2023-11-20 カリナン オンコロジー インコーポレイテッド 多重特異性結合タンパク質およびその使用方法
US10815311B2 (en) * 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
IL293780A (en) 2019-12-11 2022-08-01 Cullinan Man Inc Anti-serum albumin antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500725A (ja) 2007-10-19 2011-01-06 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SPIESS, Christoph et al.，Molecular Immunology，2015年10月，Vol. 67, No. 2，p.95-106，DOI: 10.1016/j.molimm.2015.01.003
SUURS, Frans V. et al.，Pharmacology & Therapeutics，2019年09月，Vol. 201，p.103-119，DOI: 10.1016/j.pharmthera.2019.04.006

Also Published As

Publication number Publication date
EP4073122A1 (en) 2022-10-19
WO2021119551A1 (en) 2021-06-17
EP4073122A4 (en) 2024-03-27
CN115916818A (zh) 2023-04-04
CA3161283A1 (en) 2021-06-17
JP2023506017A (ja) 2023-02-14
AU2020403273A1 (en) 2022-06-30
US20230037815A1 (en) 2023-02-09
US12428480B2 (en) 2025-09-30
IL293725A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7661446B2 (ja) 多重特異性結合タンパク質およびその使用方法
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
JP7734132B2 (ja) 抗血清アルブミン抗体
JP7780434B2 (ja) 抗ｃｄ１９抗体および多重特異性結合タンパク質
HK40091232A (zh) 抗cd19抗体和多特异性结合蛋白
KR20260020379A (ko) 다중특이적 결합 단백질의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7780434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150